[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530690":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":29,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":29,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Azacitidine Plus PD-1 therapy","EXPERIMENTAL","Patients were treated by Azacitidine plus PD-1 therapy",[13],"Drug: Azacitidine Plus PD-1 therapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients were treated by Azacytidine(75 mg\u002Fm2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)",[9],[20],"Azacitidine Plus PD-1 antibody",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066947192",null,"qlr2007@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":49,"phoneExt":29,"email":30},"Liren Qian, M.D.","+861066957676",{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Liren Qian","Vice Director","100530690","phase-2-azacitidine-plus-pd-1-therapy-for-rr-hodgkin-lymphoma-100530690",false,"NCT06190067","Azacitidine Plus PD-1 Therapy for R\u002FR Hodgkin Lymphoma","Azacitidine Plus PD-1 Therapy for Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted.\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below).\n* Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma); Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma); Hemoglobin ≥ 8 g\u002FdL.\n* Anticipated life expectancy at least 3 months.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","ALL","18 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed\u002Frefractory classic Hodgkin lymphoma.",[70,71],"Relapsed Classic Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma","2024-01-28",{"date":74,"type":75},"2024-01-30","ACTUAL",{"date":77,"type":75},"2023-10-30",{"date":79,"type":64},"2028-12",{"name":5,"class":6},1]